Company Announcement for Zelnite®
2024/7/17 TaiRx, Inc. hereby declares that Zelnite® is the only selenium injection product with a drug license approved by the Ministry of Health and Welfare (MOHW) in [...]
About Chang Lisa
This author has not yet filled in any details.So far Chang Lisa has created 51 blog entries.
TaiRx‘s injectable product, Zelnite®, has been approved by TFDA to add high dosage and change drug labeling
2024/5/9 In 2018, TaiRx received approval from the Food and Drug Administration (TFDA) of the Ministry of Health and Welfare for a new drug license, Zelnite® for [...]
TaiRx’s sodium selenite pentahydrate—SelenOne®—earned the Symbol of National Quality (SNQ) in 2022 for its affirmed safety and quality for use as a food additive.
2022/12/23 In December 2022, TaiRx’s proprietary sodium selenite pentahydrate, with the registered trademark SelenOne®, received the Symbol of National Quality (SNQ). The certification [...]
Mr. Andrew Lin’s appointment as Chairman of TaiRx, Inc. is effective as of December 9, 2020.
2020/12/9 Andrew Lin received his master’s degree of Business Administration (MBA) from the University of Chicago. He is one of the very few [...]
TaiRx’s anti-cancer drug CVM-1118 won the renewal of Excelsior Award in 2020.
2020/12/1 Having been awarded the 12th National Innovation Award in 2015 and the Excelsior Award in 2019, TaiRx’s anti-cancer drug CVM-1118 won the [...]
TaiRx successfully raised 504 million NTD in capital.
2020/11/27 To enrich working capital, TaiRx has successfully raised 504 million NTD on October 28, 2020, and issued common shares on November 27, [...]
TaiRx ranked first in Taiwan for the most innovative pharmaceutical companies in the APAC region
2019/8/30 World-renowned professional information services company, Clarivate Analytics, released a special report, “Pharmaceutical Innovation in the APAC Region – A Quantitative Company Ranking [...]
TaiRx receives “Technology and Product or Technology Development is Successful and Marketable” recommendation from Industrial Development Bureau and starts CVM-1118 (Foslinanib) Phase II clinical trial in Taiwan and US.
2019/1/2 TaiRx, Inc. (6580) announces good news at the start of 2019 that it receives “Technology and Product or Technology Development is Successful [...]
TaiRx, Inc. and BioHealth Innovation, Inc. Form TaiRx US to Develop and Commercialize Therapeutics and Precision Medicine Diagnostics- Joint venture to focus on the Nodal protein, a previously untargeted and critical mediator of aggressive cancer progression and treatment resistance
2018/10/23 TaiRx, Inc and BioHealth Innovation, Inc. (BHI) announced today the formation of TaiRx US, a new joint venture. The mission of the [...]
A major milestone for cancer drug development in Taiwan! CVM-1118 approved by the US FDA to start Phase II clinical study in the US.
2018/4/15 TaiRx’s CVM-1118 small molecule cancer drug received US FDA approval on April 15th to conduct multi-nation, multi-center Phase II clinical trial in [...]